Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16734291 | 0.81 | RORC (0.37) | — | |
| SCHEMBL29955940 | 0.80 | ENPP2 (0.36) | — | |
| SCHEMBL3635036 | 0.80 | ENPP2 (0.36) | — | |
| SCHEMBL29950796 | 0.80 | LMNA (0.35) | — | |
| SCHEMBL391293 | 0.78 | LMNA (0.43) | — | |
| SCHEMBL16734396 | 0.77 | SLC13A5 (0.33) | — | |
| SCHEMBL11962330 | 0.76 | NOS3 (0.43) | LRRK2 | |
| SCHEMBL29956843 | 0.75 | PTGS1 (0.32) | — | |
| SCHEMBL29955190 | 0.73 | CA1 (0.35) | — | |
| SCHEMBL1180451 | 0.73 | AAK1 (0.41) | LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10266532-B2 | Tricyclic modulators of TNF signaling | ABBVIE INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180179198-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-06-28 | — | — | US | disclosed |
| US-9856253-B2 | Tricyclic modulators of TNF signaling | ABBVIE, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160304517-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304517-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | TNF, TNFRSF1A, CD40 | LRRK2 2724/4885 |
| US-10266532-B2 | Tricyclic modulators of TNF signaling | TNF, TNFRSF1A, CD40 | LRRK2 2724/4885 |
| US-20180179198-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | TNF, TNFRSF1A, CD40 | LRRK2 2724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.